简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
16
2023-05
Voluntary Announcement Approval Obtained for Initiating Clinical Trial for the Novel Bispecific Antibody BA1202 in China
15
2023-05
Voluntary Announcement Patient Enrollment Completed for the Phase III Clinical Study of BA5101 in China
07
2023-05
Supplemental Notice of Annual General Meeting
04
2023-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
04
2023-05
Voluntary Announcement First Subject Enrolled in International Multi-Center Phase 3 Clinical Study of Denosumab
25
2023-04
Form of Proxy for Use at Annual General Meeting to be Held on 29 May 2023 (Applicable to Holders of H Shares)
25
2023-04
Notice of Annual General Meeting
25
2023-04
(1) 2022 Report of the Board of Directors (2) 2022 Report of the Board of Supervisors (3) 2022 Annual Report (4) Re-Appointment of Auditor (5) Remuneration of Directors (6) Remuneration of Supervisors (7) General Mandate to Issue Additional Shares (8) Pro
25
2023-04
2022 Environmental, Social and Governance Report
25
2023-04
Annual Report 2022
7
8
9
10
11
Follow me
鲁公网安备37069102000284